BioGaia

M&A Activity • May 30, 2013

Press Release 30 May 2013

BioGaia signs agreement with Nestlé for new category of products

BioGaia has today signed a new supply and licence agreement with Nestlé for the inclusion of BioGaia's patented Lactobacillus reuteri in a new category of products. This long-term agreement gives Nestlé exclusive rights to utilise this probiotic in an additional range of products in a large number of countries, with focus on emerging markets.

Lactobacillus reuteri will be added in an existing product line of Nestlé. This development has been greatly facilitated by the available clinical studies performed by BioGaia and represents a great opportunity to offer a differentiated and value-added solution to the consumers.

This is the third agreement with Nestlé after the sale of the perpetual licence to use Lactobacillus reuteri in infant nutrition products to Nestlé in February 2012. It illustrates the good collaboration between the two companies with cooperation in both the scientific as well as the commercial fields.

"We are very pleased to having been able to conclude this agreement with Nestlé as it gradually replaces a significant part of the business that we earlier sold to them. It reflects the excellent partnership established", says Peter Rothschild, President, BioGaia.

For additional information please contact Peter Rothschild, Chief Executive Officer, telephone: +46 8 555 293 00

Latest press releases from BioGaia

2013-05-13	BioGaia signs exclusive distribution agreement in China
2013-05-07	BioGaia signs exclusive distribution agreement in South Korea
2013-04-26	Annual General Meeting of BioGaia

BioGaia has published this information in accordance with the Swedish Securities Market Act. The information was issued for publication on 30 May 2013, 2:40 pm CET.

BioGaia is a healthcare company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on the lactic acid bacterium Lactobacillus reuteri which has probiotic, health-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap list of the NASDAQ OMX Nordic Exchange Stockholm. www.biogaia.com